Provider: NIHR Journals Library Content:text/plain; charset="UTF-8" TY - BOOK LB - 1. AU - National Collaborating Centre for Chronic Conditions TI - Atrial Fibrillation: National Clinical Guideline for Management in Primary and Secondary Care CY - London PB - Royal College of Physicians PY - 2006 ER - TY - JOUR LB - 2. AU - Kannel, WB AU - Wolf, PA AU - Benjamin, EJ AU - Levy, D TI - Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates J2 - Am J Cardiol PY - 1998 VL - 82 SP - 2 EP - 9N UR - http://dx.doi.org/10.1016/S0002-9149(98)00583-9 ER - TY - JOUR LB - 3. AU - Hart, RG AU - Benavente, O AU - McBride, R AU - Pearce, LA TI - Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis J2 - Ann Intern Med PY - 1999 VL - 131 SP - 492 EP - 501 UR - http://dx.doi.org/10.7326/0003-4819-131-7-199910050-00003 ER - TY - JOUR LB - 4. AU - Lee, S AU - Shafe, AC AU - Cowie, MR TI - UK stroke incidence, mortality and cardiovascular risk management 1999–2008: time-trend analysis from the General Practice Research Database J2 - BMJ Open PY - 2011 VL - 1 SP - e000269 UR - http://dx.doi.org/10.1136/bmjopen-2011-000269 ER - TY - JOUR LB - 5. AU - Soliman, EZ AU - Safford, MM AU - Muntner, P AU - Khodneva, Y AU - Dawood, FZ AU - Zakai, NA TI - Atrial fibrillation and the risk of myocardial infarction J2 - JAMA Intern Med PY - 2014 VL - 174 SP - 107 EP - 114 UR - http://dx.doi.org/10.1001/jamainternmed.2013.11912 ER - TY - JOUR LB - 6. AU - Smolina, K AU - Wright, FL AU - Rayner, M AU - Goldacre, MJ TI - Incidence and 30-day case fatality for acute myocardial infarction in England in 2010: national-linked database study J2 - Eur J Public Health PY - 2012 VL - 22 SP - 848 EP - 853 UR - http://dx.doi.org/10.1093/eurpub/ckr196 ER - TY - JOUR LB - 7. AU - Oger, E TI - Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d’Etude de la Thrombose de Bretagne Occidentale J2 - Thromb Haemost PY - 2000 VL - 83 SP - 657 EP - 660 ER - TY - BOOK LB - 8. AU - National Clinical Guideline Centre – Acute and Chronic Conditions TI - Venous Thromboembolism: Reducing the Risk of Venous Thromboembolism (Deep Vein Thrombosis and Pulmonary Embolism) in Patients Admitted to Hospital CY - London PB - Royal College of Physicians PY - 2010 ER - TY - JOUR LB - 9. AU - Connock, M AU - Stevens, C AU - Fry-Smith, A AU - Jowett, S AU - Fitzmaurice, D AU - Moore, D AU - Song, F TI - Clinical effectiveness and cost-effectiveness of different models of managing long-term oral anticoagulation therapy: a systematic review and economic modelling J2 - Health Technol Assess PY - 2007 VL - 11 IS - 38 UR - http://dx.doi.org/10.3310/hta11380 ER - TY - JOUR LB - 10. AU - Pirmohamed, M AU - James, S AU - Meakin, S AU - Green, C AU - Scott, AK AU - Walley, TJ TI - Adverse drug reactions as cause of admission to hospital: prospective analysis of 18820 patients J2 - BMJ PY - 2004 VL - 329 SP - 15 EP - 19 UR - http://dx.doi.org/10.1136/bmj.329.7456.15 ER - TY - BOOK LB - 11. AU - National Institute for Health and Clinical Excellence (NICE) TI - Clinical Guideline 36. National Cost Impact Report to accompany ‘Atrial Fibrillation: the Management of Atrial Fibrillation’ CY - London PB - NICE PY - 2006 ER - TY - JOUR LB - 12. AU - Garcia, D AU - Libby, E AU - Crowther, MA TI - The new oral anticoagulants J2 - Blood PY - 2010 VL - 115 SP - 15 EP - 20 UR - http://dx.doi.org/10.1182/blood-2009-09-241851 ER - TY - JOUR LB - 13. AU - Reilly, PA AU - Lehr, T AU - Haertter, S AU - Connolly, SJ AU - Yusuf, S AU - Eikelboom, JW TI - The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy) J2 - J Am Coll Cardiol PY - 2014 VL - 63 SP - 321 EP - 328 UR - http://dx.doi.org/10.1016/j.jacc.2013.07.104 ER - TY - BOOK LB - 14. AU - Centre for Reviews and Dissemination (CRD) TI - Systematic Reviews. CRD’s Guidance for Undertaking Reviews in Health Care ET - 3rd edn. CY - York PB - CRD, University of York PY - 2009 ER - TY - BOOK LB - 15. AU - Higgins, JPT AU - Green, S TI - Cochrane Handbook for Systematic Reviews of Interventions CY - Chichester PB - Wiley PY - 2008 UR - http://dx.doi.org/10.1002/9780470712184 ER - TY - JOUR LB - 16. AU - Assiri, A AU - Al-Majzoub, O AU - Kanaan, AO AU - Donovan, JL AU - Silva, M TI - Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation J2 - Clin Ther PY - 2013 VL - 35 SP - 967 EP - 84.e2 UR - http://dx.doi.org/10.1016/j.clinthera.2013.05.011 ER - TY - JOUR LB - 17. AU - Castellucci, LA AU - Cameron, C AU - Le Gal, G AU - Rodger, MA AU - Coyle, D AU - Wells, PS TI - Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis J2 - BMJ PY - 2013 VL - 347 SP - f5133 UR - http://dx.doi.org/10.1136/bmj.f5133 ER - TY - JOUR LB - 18. AU - Fox, BD AU - Kahn, SR AU - Langleben, D AU - Eisenberg, MJ AU - Shimony, A TI - Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials J2 - BMJ PY - 2012 VL - 345 SP - e7498 UR - http://dx.doi.org/10.1136/bmj.e7498 ER - TY - JOUR LB - 19. AU - Higgins, JP AU - Altman, DG AU - Gøtzsche, PC AU - Jüni, P AU - Moher, D AU - Oxman, AD TI - The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials J2 - BMJ PY - 2011 VL - 343 SP - d5928 UR - http://dx.doi.org/10.1136/bmj.d5928 ER - TY - JOUR LB - 20. AU - Lu, G AU - Ades, AE TI - Combination of direct and indirect evidence in mixed treatment comparisons J2 - Stat Med PY - 2004 VL - 23 SP - 3105 EP - 3124 UR - http://dx.doi.org/10.1002/sim.1875 ER - TY - JOUR LB - 21. AU - Caldwell, DM AU - Ades, AE AU - Higgins, JP TI - Simultaneous comparison of multiple treatments: combining direct and indirect evidence J2 - BMJ PY - 2005 VL - 331 SP - 897 EP - 900 UR - http://dx.doi.org/10.1136/bmj.331.7521.897 ER - TY - JOUR LB - 22. AU - Dias, S AU - Sutton, AJ AU - Ades, AE AU - Welton, NJ TI - Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials J2 - Med Decis Making PY - 2013 VL - 33 SP - 607 EP - 617 UR - http://dx.doi.org/10.1177/0272989X12458724 ER - TY - JOUR LB - 23. AU - Spiegelhalter, DJ AU - Best, NG AU - Carlin, BP AU - van der Linde, A TI - Bayesian measures of model complexity and fit J2 - J R Statist Soc B PY - 2002 VL - 64 SP - 583 EP - 616 UR - http://dx.doi.org/10.1111/1467-9868.00353 ER - TY - JOUR LB - 24. AU - Berkey, CS AU - Hoaglin, DC AU - Mosteller, F AU - Colditz, GA TI - A random-effects regression model for meta-analysis J2 - Stat Med PY - 1995 VL - 14 SP - 395 EP - 411 UR - http://dx.doi.org/10.1002/sim.4780140406 ER - TY - JOUR LB - 25. AU - Salanti, G AU - Higgins, JP AU - Ades, AE AU - Ioannidis, JP TI - Evaluation of networks of randomized trials J2 - Stat Methods Med Res PY - 2008 VL - 17 SP - 279 EP - 301 UR - http://dx.doi.org/10.1177/0962280207080643 ER - TY - JOUR LB - 26. AU - Song, F AU - Altman, DG AU - Glenny, AM AU - Deeks, JJ TI - Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses J2 - BMJ PY - 2003 VL - 326 SP - 472 EP - 475 UR - http://dx.doi.org/10.1136/bmj.326.7387.472 ER - TY - JOUR LB - 27. AU - Dias, S AU - Welton, NJ AU - Caldwell, DM AU - Ades, AE TI - Checking consistency in mixed treatment comparison meta-analysis J2 - Stat Med PY - 2010 VL - 29 SP - 932 EP - 944 UR - http://dx.doi.org/10.1002/sim.3767 ER - TY - CHAP LB - 28. AU - Dias, S AU - Welton, NJ AU - Sutton, AJ AU - Ades, AE TI - NICE DSU Technical Support Document 2 T2 - A Generalised Linear Modelling Framework for Pairwise and Network Meta-analysis of Randomised Controlled Trials CY - London PB - NICE PY - 2011 ER - TY - ELEC LB - 29. AU - The R Foundation TI - The R Project for Statistical Computing UR - www.r-project.org/ M1 - 12 August 2016 ER - TY - JOUR LB - 30. AU - Lunn, DJ AU - Thomas, A AU - Best, N AU - Spiegelhalter, DJ TI - WinBUGS – a Bayesian modelling framework: concepts, structure, and extensibility J2 - Stat Comput PY - 2000 VL - 10 SP - 325 EP - 337 UR - http://dx.doi.org/10.1023/A:1008929526011 ER - TY - JOUR LB - 31. AU - Gage, BF AU - Cardinalli, AB AU - Albers, GW AU - Owens, DK TI - Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation J2 - JAMA PY - 1995 VL - 274 SP - 1839 EP - 1845 UR - http://dx.doi.org/10.1001/jama.1995.03530230025025 ER - TY - JOUR LB - 32. AU - Lightowlers, S AU - McGuire, A TI - Cost-effectiveness of anticoagulation in nonrheumatic atrial fibrillation in the primary prevention of ischemic stroke J2 - Stroke PY - 1998 VL - 29 SP - 1827 EP - 1832 UR - http://dx.doi.org/10.1161/01.STR.29.9.1827 ER - TY - BOOK LB - 33. AU - Bayer plc TI - Single Technology Appraisal (STA) of Rivaroxaban (Xarelto) CY - Newbury PB - Bayer plc PY - 2011 ER - TY - JOUR LB - 34. AU - Shah, SV AU - Gage, BF TI - Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation J2 - Circulation PY - 2011 VL - 123 SP - 2562 EP - 2570 UR - http://dx.doi.org/10.1161/CIRCULATIONAHA.110.985655 ER - TY - JOUR LB - 35. AU - Freeman, JV AU - Zhu, RP AU - Owens, DK AU - Garber, AM AU - Hutton, DW AU - Go, AS TI - Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation J2 - Ann Intern Med PY - 2011 VL - 154 SP - 1 EP - 11 UR - http://dx.doi.org/10.7326/0003-4819-154-1-201101040-00289 ER - TY - JOUR LB - 36. AU - Lee, S AU - Mullin, R AU - Blazawski, J AU - Coleman, CI TI - Cost-effectiveness of apixaban compared with warfarin for stroke prevention in atrial fibrillation J2 - PLOS ONE PY - 2012 VL - 7 SP - e47473 UR - http://dx.doi.org/10.1371/journal.pone.0047473 ER - TY - JOUR LB - 37. AU - Lee, S AU - Anglade, MW AU - Pham, D AU - Pisacane, R AU - Kluger, J AU - Coleman, CI TI - Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation J2 - Am J Cardiol PY - 2012 VL - 110 SP - 845 EP - 851 UR - http://dx.doi.org/10.1016/j.amjcard.2012.05.011 ER - TY - JOUR LB - 38. AU - Harrington, AR AU - Armstrong, EP AU - Nolan, PE AU - Malone, DC TI - Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation J2 - Stroke PY - 2013 VL - 44 SP - 1676 EP - 1681 UR - http://dx.doi.org/10.1161/STROKEAHA.111.000402 ER - TY - JOUR LB - 39. AU - Kamel, H AU - Easton, JD AU - Johnston, SC AU - Kim, AS TI - Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation J2 - Neurology PY - 2012 VL - 79 SP - 1428 EP - 1434 UR - http://dx.doi.org/10.1212/WNL.0b013e31826d5fe8 ER - TY - BOOK LB - 40. AU - Wells, G AU - Coyle, D AU - Cameron, C AU - Steiner, S AU - Coyle, K AU - Kelly, S TI - Safety, Effectiveness, and Cost-Effectiveness of New Oral Anticoagulants Compared with Warfarin in Preventing Stroke and Other Cardiovascular Events in Patients with Atrial Fibrillation CY - Ottawa, ON PB - Canadian Collaborative for Drug Safety, Effectiveness and Network Meta-Analysis PY - 2012 ER - TY - BOOK LB - 41. AU - Wisloff, T AU - Tove, R AU - Gunhild, H AU - Asmund, R AU - Marianne, K TI - Efficacy and Cost-effectiveness of New Oral Anticoagulants Compared to Warfarin for the Prevention of Stroke in Patients with Atrial Fibrillation CY - Oslo PB - Kunnskapssenteret PY - 2013 ER - TY - JOUR LB - 42. AU - Kansal, AR AU - Sorensen, SV AU - Gani, R AU - Robinson, P AU - Pan, F AU - Plumb, JM AU - Cowie, MR TI - Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation J2 - Heart PY - 2012 VL - 98 SP - 573 EP - 578 UR - http://dx.doi.org/10.1136/heartjnl-2011-300646 ER - TY - JOUR LB - 43. AU - Canestaro, WJ AU - Patrick, AR AU - Avorn, J AU - Ito, K AU - Matlin, OS AU - Brennan, TA TI - Cost-effectiveness of oral anticoagulants for treatment of atrial fibrillation J2 - Circ Cardiovasc Qual Outcomes PY - 2013 VL - 6 SP - 724 EP - 731 UR - http://dx.doi.org/10.1161/CIRCOUTCOMES.113.000661 ER - TY - JOUR LB - 44. AU - Nshimyumukiza, L AU - Duplantie, J AU - Gagnon, M AU - Douville, X AU - Fournier, D AU - Lindsay, C TI - Dabigatran versus warfarin under standard or pharmacogenetic-guided management for the prevention of stroke and systemic thromboembolism in patients with atrial fibrillation: a cost/utility analysis using an analytic decision model J2 - Thromb J PY - 2013 VL - 11 SP - 14 UR - http://dx.doi.org/10.1186/1477-9560-11-14 ER - TY - JOUR LB - 45. AU - Krejczy, M AU - Harenberg, J AU - Marx, S AU - Obermann, K AU - Frölich, L AU - Wehling, M TI - Comparison of cost-effectiveness of anticoagulation with dabigatran, rivaroxaban and apixaban in patients with non-valvular atrial fibrillation across countries J2 - J Thromb Thrombolysis PY - 2014 VL - 37 SP - 507 EP - 523 UR - http://dx.doi.org/10.1007/s11239-013-0989-6 ER - TY - JOUR LB - 46. AU - Pink, J AU - Lane, S AU - Pirmohamed, M AU - Hughes, DA TI - Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses J2 - BMJ PY - 2011 VL - 343 SP - d6333 UR - http://dx.doi.org/10.1136/bmj.d6333 ER - TY - JOUR LB - 47. AU - Lip, GY AU - Kongnakorn, T AU - Phatak, H AU - Kuznik, A AU - Lanitis, T AU - Liu, LZ TI - Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation J2 - Clin Ther PY - 2014 VL - 36 SP - 192 EP - 210.e20 UR - http://dx.doi.org/10.1016/j.clinthera.2013.12.011 ER - TY - JOUR LB - 48. AU - Rognoni, C AU - Marchetti, M AU - Quaglini, S AU - Liberato, NL TI - Apixaban, dabigatran, and rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis J2 - Clin Drug Investig PY - 2014 VL - 34 SP - 9 EP - 17 UR - http://dx.doi.org/10.1007/s40261-013-0144-3 ER - TY - JOUR LB - 49. AU - Limone, BL AU - Baker, WL AU - Mearns, ES AU - White, CM AU - Kluger, J AU - Coleman, CI TI - Common flaws exist in published cost-effectiveness models of pharmacologic stroke prevention in atrial fibrillation J2 - J Clin Epidemiol PY - 2014 VL - 67 SP - 1093 EP - 1102 UR - http://dx.doi.org/10.1016/j.jclinepi.2014.05.013 ER - TY - GEN LB - 50. AU - Bayer TI - Rivaroxaban for the Treatment of Deep Vein Thrombosis and Prevention of Recurrent Deep Vein Thrombosis and Pulmonary Embolism PY - 2012 ER - TY - GEN LB - 51. AU - Bayer TI - Rivaroxaban for Treating Pulmonary Embolism and Preventing Recurrent Venous Thromboembolism PY - 2013 ER - TY - GEN LB - 52. AU - Boehringer Ingelheim TI - Dabigatran Etexilate for the Prevention of Venous Thromboembolism After Hip or Knee Replacement Surgery in Adults PY - 2008 ER - TY - JOUR LB - 53. AU - Botteman, MF AU - Caprini, J AU - Stephens, JM AU - Nadipelli, V AU - Bell, CF AU - Pashos, CL TI - Results of an economic model to assess the cost-effectiveness of enoxaparin, a low-molecular-weight heparin, versus warfarin for the prophylaxis of deep vein thrombosis and associated long-term complications in total hip replacement surgery in the United States J2 - Clin Ther PY - 2002 VL - 24 SP - 1960 EP - 1986 UR - http://dx.doi.org/10.1016/S0149-2918(02)80091-1 ER - TY - GEN LB - 54. AU - Bayer TI - Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults PY - 2009 ER - TY - GEN LB - 55. AU - Bristol-Myers Squibb TI - Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults PY - 2012 ER - TY - JOUR LB - 56. AU - Dranitsaris, G AU - Stumpo, C AU - Smith, R AU - Bartle, W TI - Extended dalteparin prophylaxis for venous thromboembolic events: cost-utility analysis in patients undergoing major orthopedic surgery J2 - Am J Cardiovasc Drugs PY - 2009 VL - 9 SP - 45 EP - 58 UR - http://dx.doi.org/10.1007/BF03256594 ER - TY - JOUR LB - 57. AU - Duran, A AU - Sengupta, N AU - Diamantopoulos, A AU - Forster, F AU - Kwong, L AU - Lees, M TI - Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a U.S. payer’s perspective J2 - Pharmacoeconomics PY - 2012 VL - 30 SP - 87 EP - 101 UR - http://dx.doi.org/10.2165/11599370-000000000-00000 ER - TY - JOUR LB - 58. AU - Monreal, M AU - Folkerts, K AU - Diamantopoulos, A AU - Imberti, D AU - Brosa, M TI - Cost-effectiveness impact of rivaroxaban versus new and existing prophylaxis for the prevention of venous thromboembolism after total hip or knee replacement surgery in France, Italy and Spain J2 - Thromb Haemost PY - 2013 VL - 110 SP - 987 EP - 994 UR - http://dx.doi.org/10.1160/TH12-12-0919 ER - TY - JOUR LB - 59. AU - Mahmoudi, M AU - Sobieraj, DM TI - The cost-effectiveness of oral direct factor Xa inhibitors compared with low-molecular-weight heparin for the prevention of venous thromboembolism prophylaxis in total hip or knee replacement surgery J2 - Pharmacotherapy PY - 2013 VL - 33 SP - 1333 EP - 1340 UR - http://dx.doi.org/10.1002/phar.1269 ER - TY - JOUR LB - 60. AU - McCullagh, L AU - Tilson, L AU - Walsh, C AU - Barry, M TI - A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the Irish healthcare setting J2 - PharmacoEconomics PY - 2009 VL - 27 SP - 829 EP - 846 UR - http://dx.doi.org/10.2165/11313800-000000000-00000 ER - TY - JOUR LB - 61. AU - McCullagh, L AU - Walsh, C AU - Barry, M TI - Value-of-information analysis to reduce decision uncertainty associated with the choice of thromboprophylaxis after total hip replacement in the Irish healthcare setting J2 - PharmacoEconomics PY - 2012 VL - 30 SP - 941 EP - 959 UR - http://dx.doi.org/10.2165/11591510-000000000-00000 ER - TY - JOUR LB - 62. AU - Lundkvist, J AU - Bergqvist, D AU - Jönsson, B TI - Cost-effectiveness of extended prophylaxis with fondaparinux compared with low molecular weight heparin against venous thromboembolism in patients undergoing hip fracture surgery J2 - Eur J Health Econ PY - 2007 VL - 8 SP - 313 EP - 323 UR - http://dx.doi.org/10.1007/s10198-006-0017-2 ER - TY - JOUR LB - 63. AU - Gordois, A AU - Posnett, J AU - Borris, L AU - Bossuyt, P AU - Jönsson, B AU - Levy, E AU - de Pouvourville, G TI - The cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopedic surgery J2 - J Thromb Haemost PY - 2003 VL - 1 SP - 2167 EP - 2174 UR - http://dx.doi.org/10.1046/j.1538-7836.2003.00396.x ER - TY - JOUR LB - 64. AU - Pishko, AM AU - Smith, KJ AU - Ragni, MV TI - Anticoagulation in ambulatory cancer patients with no indication for prophylactic or therapeutic anticoagulation: a cost-effectiveness analysis from a U.S. perspective J2 - Thromb Haemost PY - 2012 VL - 108 SP - 303 EP - 310 UR - http://dx.doi.org/10.1160/TH12-03-0185 ER - TY - JOUR LB - 65. AU - Sullivan, SD AU - Kwong, L AU - Nutescu, E TI - Cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against venous thromboembolism in patients undergoing hip fracture surgery J2 - Value Health PY - 2006 VL - 9 SP - 68 EP - 76 ER - TY - JOUR LB - 66. AU - Zindel, S AU - Stock, S AU - Müller, D AU - Stollenwerk, B TI - A multi-perspective cost-effectiveness analysis comparing rivaroxaban with enoxaparin sodium for thromboprophylaxis after total hip and knee replacement in the German healthcare setting J2 - BMC Health Serv Res PY - 2012 VL - 12 SP - 192 UR - http://dx.doi.org/10.1186/1472-6963-12-192 ER - TY - JOUR LB - 67. AU - Gómez-Outes, A AU - Terleira-Fernández, AI AU - Suárez-Gea, ML AU - Vargas-Castrillón, E TI - Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons J2 - BMJ PY - 2012 VL - 344 SP - e3675 UR - http://dx.doi.org/10.1136/bmj.e3675 ER - TY - BOOK LB - 68. AU - National Institute for Health and Clinical Excellence (NICE) TI - Atrial Fibrillation: The Management of Atrial Fibrillation CY - London PB - NICE PY - 2006 ER - TY - ELEC LB - 69. AU - National Joint Registry Editorial Board TI - 10th Annual Report CY - Hemel Hempstead PB - National Joint Registry for England, Wales and Northern Ireland PY - 2013 UR - www.njrcentre.org.uk/njrcentre/Portals/0/Documents/England/Reports/10th_annual_report/NJR%2010th%20Annual%20Report%202013%20B.pdf M1 - 4 April 2015 ER - TY - ELEC LB - 70. AU - National Institute for Health and Care Excellence (NICE) TI - National Clinical Guideline Centre – Acute and Chronic Conditions. Venous Thromboembolism: Reducing the Risk of Venous Thromboembolism (Deep Vein Thrombosis and Pulmonary Embolism) in Patients Admitted to Hospital. Methods, Evidence and Guidance CY - London PB - National Clinical Guideline Centre – Acute and Chronic Conditions PY - 2010 UR - www.nice.org.uk/guidance/cg92/evidence/full-guideline-243920125 M1 - 29 September 2016 ER - TY - BOOK LB - 71. AU - National Institute for Health and Care Excellence (NICE) TI - Venous Thromboembolism: Reducing the Risk of Venous Thromboembolism (Deep Vein Thrombosis and Pulmonary Embolism) in Patients Admitted to Hospital CY - London PB - NICE PY - 2010 UR - www.nice.org.uk/guidance/cg92 ER - TY - BOOK LB - 72. AU - Briggs, A AU - Sculpher, M AU - Claxton, K TI - Decision Modelling for Health Economic Evaluation CY - Oxford PB - Oxford University Press PY - 2006 ER - TY - BOOK LB - 73. AU - National Institute for Health and Care Excellence (NICE) TI - Guide to the Methods of Technology Appraisal 2013 CY - London PB - NICE PY - 2013 ER - TY - JOUR LB - 74. AU - Fenwick, E AU - Claxton, K AU - Sculpher, M TI - Representing uncertainty: the role of cost-effectiveness acceptability curves J2 - Health Econ PY - 2001 VL - 10 SP - 779 EP - 787 UR - http://dx.doi.org/10.1002/hec.635 ER - TY - GEN LB - 75. AU - Strong, M BP AU - Thomas, C AU - Brennan, A TI - Sheffield Accelerated Value of Information PY - 2015 Y2 - July 2015 ER - TY - JOUR LB - 76. AU - Strong, M AU - Oakley, JE AU - Brennan, A TI - Estimating multiparameter partial expected value of perfect information from a probabilistic sensitivity analysis sample: a nonparametric regression approach J2 - Med Decis Making PY - 2014 VL - 34 SP - 311 EP - 326 UR - http://dx.doi.org/10.1177/0272989X13505910 ER - TY - JOUR LB - 77. AU - Hori, M AU - Connolly, SJ AU - Zhu, J AU - Liu, LS AU - Lau, CP AU - Pais, P TI - Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation J2 - Stroke PY - 2013 VL - 44 SP - 1891 EP - 1896 UR - http://dx.doi.org/10.1161/STROKEAHA.113.000990 ER - TY - JOUR LB - 78. AU - Naimark, DM AU - Bott, M AU - Krahn, M TI - The half-cycle correction explained: two alternative pedagogical approaches J2 - Med Decis Making PY - 2008 VL - 28 SP - 706 EP - 712 UR - http://dx.doi.org/10.1177/0272989X08315241 ER - TY - JOUR LB - 79. AU - Ali, A AU - Bailey, C AU - Abdelhafiz, AH TI - Stroke prophylaxis with warfarin or dabigatran for patients with non-valvular atrial fibrillation-cost analysis J2 - Age Ageing PY - 2012 VL - 41 SP - 681 EP - 684 UR - http://dx.doi.org/10.1093/ageing/afs017 ER - TY - BOOK LB - 80. AU - Office for National Statistics (ONS) TI - ONS Consumer Price Inflation Index for Medical Services (DKC3) for 2013/14 CY - London PB - ONS PY - 2013 UR - www.ons.gov.uk/ons/publications/re-reference-tables.html?edition=tcm%3A77–323625,%202015%20#29 Y2 - 1 November 2015 ER - TY - BOOK LB - 81. AU - Department of Health (DH) TI - NHS Reference Costs 2012–13 CY - London PB - DH PY - 2014 ER - TY - JOUR LB - 82. AU - Ioannides-Demos, LL AU - Makarounas-Kirchmann, K AU - Ashton, E AU - Stoelwinder, J AU - McNeil, JJ TI - Cost of myocardial infarction to the Australian community: a prospective, multicentre survey J2 - Clin Drug Investig PY - 2010 VL - 30 SP - 533 EP - 543 UR - http://dx.doi.org/10.2165/11536350-000000000-00000 ER - TY - JOUR LB - 83. AU - Luengo-Fernandez, R AU - Yiin, GS AU - Gray, AM AU - Rothwell, PM TI - Population-based study of acute- and long-term care costs after stroke in patients with AF J2 - Int J Stroke PY - 2013 VL - 8 SP - 308 EP - 314 UR - http://dx.doi.org/10.1111/j.1747-4949.2012.00812.x ER - TY - BOOK LB - 84. AU - National Institute for Health and Clinical Excellence (NICE) TI - Dabigatran Etexilate for the Prevention of Venous Thromboembolism After Hip or Knee Replacement Surgery in Adults CY - London PB - NICE PY - 2008 ER - TY - JOUR LB - 85. AU - Caprini, JA AU - Botteman, MF AU - Stephens, JM AU - Nadipelli, V AU - Ewing, MM AU - Brandt, S TI - Economic burden of long-term complications of deep vein thrombosis after total hip replacement surgery in the United States J2 - Value Health PY - 2003 VL - 6 SP - 59 EP - 64 UR - http://dx.doi.org/10.1046/j.1524-4733.2003.00204.x ER - TY - JOUR LB - 86. AU - Locadia, M AU - Bossuyt, PM AU - Stalmeier, PF AU - Sprangers, MA AU - van Dongen, CJ AU - Middeldorp, S TI - Treatment of venous thromboembolism with vitamin K antagonists: patients’ health state valuations and treatment preferences J2 - Thromb Haemost PY - 2004 VL - 92 SP - 1336 EP - 1341 UR - http://dx.doi.org/10.1160/th04-02-0075 ER - TY - JOUR LB - 87. AU - Berg, J AU - Lindgren, P AU - Nieuwlaat, R AU - Bouin, O AU - Crijns, H TI - Factors determining utility measured with the EQ-5D in patients with atrial fibrillation J2 - Qual Life Res PY - 2010 VL - 19 SP - 381 EP - 390 UR - http://dx.doi.org/10.1007/s11136-010-9591-y ER - TY - JOUR LB - 88. AU - Robinson, A AU - Thomson, R AU - Parkin, D AU - Sudlow, M AU - Eccles, M TI - How patients with atrial fibrillation value different health outcomes: a standard gamble study J2 - J Health Serv Res Policy PY - 2001 VL - 6 SP - 92 EP - 98 UR - http://dx.doi.org/10.1258/1355819011927288 ER - TY - JOUR LB - 89. AU - Lenert, L AU - Soetikno, RM TI - Automated computer interviews to elicit utilities: potential applications in the treatment of deep venous thrombosis J2 - JAMA PY - 1997 VL - 4 SP - 49 EP - 56 UR - http://dx.doi.org/10.1136/jamia.1997.0040049 ER - TY - JOUR LB - 90. AU - Lacey, EA AU - Walters, SJ TI - Continuing inequality: gender and social class influences on self perceived health after a heart attack J2 - J Epidemiol Community Health PY - 2003 VL - 57 SP - 622 EP - 627 UR - http://dx.doi.org/10.1136/jech.57.8.622 ER - TY - JOUR LB - 91. AU - Haacke, C AU - Althaus, A AU - Spottke, A AU - Siebert, U AU - Back, T AU - Dodel, R TI - Long-term outcome after stroke: evaluating health-related quality of life using utility measurements J2 - Stroke PY - 2006 VL - 37 SP - 193 EP - 198 UR - http://dx.doi.org/10.1161/01.STR.0000196990.69412.fb ER - TY - BOOK LB - 92. AU - Kind, P AU - Hardman, G AU - Macran, S TI - UK Population Norms for EQ-5D CY - York PB - Centre for Health Economics, University of York PY - 1999 ER - TY - JOUR LB - 93. AU - Meads, DM AU - McKenna, SP AU - Doughty, N AU - Das, C AU - Gin-Sing, W AU - Langley, J AU - Pepke-Zaba, J TI - The responsiveness and validity of the CAMPHOR Utility Index J2 - Eur Respir J PY - 2008 VL - 32 SP - 1513 EP - 1519 UR - http://dx.doi.org/10.1183/09031936.00069708 ER - TY - JOUR LB - 94. AU - McKenna, SP AU - Ratcliffe, J AU - Meads, DM AU - Brazier, JE TI - Development and validation of a preference based measure derived from the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for use in cost utility analyses J2 - Health Qual Life Outcomes PY - 2008 VL - 6 SP - 65 UR - http://dx.doi.org/10.1186/1477-7525-6-65 ER - TY - JOUR LB - 95. AU - Petersen, P AU - Boysen, G AU - Godtfredsen, J AU - Andersen, ED AU - Andersen, B TI - Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study J2 - Lancet PY - 1989 VL - 1 SP - 175 EP - 179 UR - http://dx.doi.org/10.1016/S0140-6736(89)91200-2 ER - TY - JOUR LB - 96. AU - Stroke Prevention in Atrial Fibrillation Investigators TI - Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study J2 - Lancet PY - 1994 VL - 343 SP - 687 EP - 691 ER - TY - JOUR LB - 97. AU - Gulløv, AL AU - Koefoed, BG AU - Petersen, P AU - Pedersen, TS AU - Andersen, ED AU - Godtfredsen, J AU - Boysen, G TI - Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study J2 - Arch Intern Med PY - 1998 VL - 158 SP - 1513 EP - 1521 UR - http://dx.doi.org/10.1001/archinte.158.14.1513 ER - TY - JOUR LB - 98. AU - Hellemons, BS AU - Langenberg, M AU - Lodder, J AU - Vermeer, F AU - Schouten, HJ AU - Lemmens, T TI - Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin J2 - BMJ PY - 1999 VL - 319 SP - 958 EP - 964 UR - http://dx.doi.org/10.1136/bmj.319.7215.958 ER - TY - JOUR LB - 99. AU - Hu, DY AU - Zhang, HP AU - Sun, YH AU - Jiang, LQ AU - Antithrombotic Therapy in Atrial Fibrillation Study Group TI - The randomized study of efficiency and safety of antithrombotic therapy in nonvalvular atrial fibrillation: warfarin compared with aspirin J2 - Zhonghua Xin Xue Guan Bing Za Zhi PY - 2006 VL - 34 SP - 295 EP - 298 ER - TY - JOUR LB - 100. AU - Connolly, S AU - Pogue, J AU - Hart, R AU - Pfeffer, M AU - Hohnloser, S AU - Chrolavicius, S TI - Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial J2 - Lancet PY - 2006 VL - 367 SP - 1903 EP - 1912 UR - http://dx.doi.org/10.1016/S0140-6736(06)68845-4 ER - TY - JOUR LB - 101. AU - Rash, A AU - Downes, T AU - Portner, R AU - Yeo, WW AU - Morgan, N AU - Channer, KS TI - A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO) J2 - Age Ageing PY - 2007 VL - 36 SP - 151 EP - 156 UR - http://dx.doi.org/10.1093/ageing/afl129 ER - TY - JOUR LB - 102. AU - Ezekowitz, MD AU - Reilly, PA AU - Nehmiz, G AU - Simmers, TA AU - Nagarakanti, R AU - Parcham-Azad, K TI - Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study) J2 - Am J Cardiol PY - 2007 VL - 100 SP - 1419 EP - 1426 UR - http://dx.doi.org/10.1016/j.amjcard.2007.06.034 ER - TY - JOUR LB - 103. AU - Mant, J AU - Hobbs, FD AU - Fletcher, K AU - Roalfe, A AU - Fitzmauricie, D AU - Lip, GY TI - Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial J2 - Lancet PY - 2007 VL - 370 SP - 493 EP - 503 UR - http://dx.doi.org/10.1016/S0140-6736(07)61233-1 ER - TY - JOUR LB - 104. AU - Connolly, SJ AU - Ezekowitz, MD AU - Yusuf, S AU - Eikelboom, J AU - Oldgren, J AU - Parekh, A TI - Dabigatran versus warfarin in patients with atrial fibrillation J2 - N Engl J Med PY - 2009 VL - 361 SP - 1139 EP - 1151 UR - http://dx.doi.org/10.1056/NEJMoa0905561 ER - TY - JOUR LB - 105. AU - Eikelboom, JW AU - O’Donnell, M AU - Yusuf, S AU - Diaz, R AU - Flaker, G AU - Hart, R TI - Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment J2 - Am Heart J PY - 2010 VL - 159 SP - 348 EP - 53.e1 UR - http://dx.doi.org/10.1016/j.ahj.2009.08.026 ER - TY - JOUR LB - 106. AU - ROCKET, AF AU - Study Investigators TI - Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: Rationale and Design of the ROCKET AF study J2 - Am Heart J PY - 2010 VL - 159 SP - 340 EP - 7.e1 UR - http://dx.doi.org/10.1016/j.ahj.2009.11.025 ER - TY - JOUR LB - 107. AU - Lopes, RD AU - Alexander, JH AU - Al-Khatib, SM AU - Ansell, J AU - Diaz, R AU - Easton, JD TI - Apixaban for reduction in stroke and other Thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale J2 - Am Heart J PY - 2010 VL - 159 SP - 331 EP - 339 UR - http://dx.doi.org/10.1016/j.ahj.2009.07.035 ER - TY - JOUR LB - 108. AU - Weitz, JI AU - Connolly, SJ AU - Patel, I AU - Salazar, D AU - Rohatagi, S AU - Mendell, J TI - Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation J2 - Thromb Haemost PY - 2010 VL - 104 SP - 633 EP - 641 UR - http://dx.doi.org/10.1160/TH10-01-0066 ER - TY - JOUR LB - 109. AU - Connolly, SJ AU - Ezekowitz, MD AU - Yusuf, S AU - Reilly, PA AU - Wallentin, L AU - Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators TI - Newly identified events in the RE-LY trial J2 - N Engl J Med PY - 2010 VL - 363 SP - 1875 EP - 1876 UR - http://dx.doi.org/10.1056/NEJMc1007378 ER - TY - GEN LB - 110. AU - Yamaguchi, T TI - A Dose Response Study of Dabigatran Etexilate (BIBR 1048) in Pharmacodynamics and Safety in Patients with Non-valvular Atrial Fibrillation in Comparison to Warfarin PY - 2010 ER - TY - JOUR LB - 111. AU - Ruff, CT AU - Giugliano, RP AU - Antman, EM AU - Crugnale, SE AU - Bocanegra, T AU - Mercuri, M TI - Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48) J2 - Am Heart J PY - 2010 VL - 160 SP - 635 EP - 641 UR - http://dx.doi.org/10.1016/j.ahj.2010.06.042 ER - TY - JOUR LB - 112. AU - Patel, MR AU - Mahaffey, KW AU - Garg, J AU - Pan, G AU - Singer, DE AU - Hacke, W TI - Rivaroxaban versus warfarin in nonvalvular atrial fibrillation J2 - N Engl J Med PY - 2011 VL - 365 SP - 883 EP - 891 UR - http://dx.doi.org/10.1056/NEJMoa1009638 ER - TY - JOUR LB - 113. AU - Ogawa, S AU - Shinohara, Y AU - Kanmuri, K TI - Safety and efficacy of the oral direct factor Xa inhibitor apixaban in Japanese patients with non-valvular atrial fibrillation – The ARISTOTLE-J study J2 - Circ J PY - 2011 VL - 75 SP - 1852 EP - 1859 UR - http://dx.doi.org/10.1253/circj.CJ-10-1183 ER - TY - JOUR LB - 114. AU - Granger, CB AU - Alexander, JH AU - McMurray, JJ AU - Lopes, RD AU - Hylek, EM AU - Hanna, M TI - Apixaban versus warfarin in patients with atrial fibrillation J2 - N Engl J Med PY - 2011 VL - 365 SP - 981 EP - 992 UR - http://dx.doi.org/10.1056/NEJMoa1107039 ER - TY - JOUR LB - 115. AU - Chung, N AU - Jeon, HK AU - Lien, LM AU - Lai, WT AU - Tse, HF AU - Chung, WS TI - Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation J2 - Thromb Haemost PY - 2011 VL - 105 SP - 535 EP - 544 UR - http://dx.doi.org/10.1160/TH10-07-0451 ER - TY - JOUR LB - 116. AU - Hohnloser, S AU - Yusuf, S AU - Eikelboom, J AU - Steg, G AU - Atar, D AU - Budaj, A TI - Apixaban in patients with atrial fibrillation and their risk for cardiovascular hospitalization: insights from the AVERROES trial J2 - Eur Heart J PY - 2011 VL - 32 SP - 671 ER - TY - JOUR LB - 117. AU - Connolly, SJ AU - Eikelboom, J AU - Joyner, C AU - Diener, HC AU - Hart, R AU - Golitsyn, S TI - Apixaban in patients with atrial fibrillation J2 - N Engl J Med PY - 2011 VL - 364 SP - 806 EP - 817 UR - http://dx.doi.org/10.1056/NEJMoa1007432 ER - TY - JOUR LB - 118. AU - Yamashita, T AU - Koretsune, Y AU - Yasaka, M AU - Inoue, H AU - Kawai, Y AU - Yamaguchi, T TI - Randomized, multicenter, warfarin-controlled phase II study of edoxaban in Japanese patients with non-valvular atrial fibrillation J2 - Circ J PY - 2012 VL - 76 SP - 1840 EP - 1847 UR - http://dx.doi.org/10.1253/circj.CJ-11-1140 ER - TY - JOUR LB - 119. AU - Hohnloser, SH AU - Hijazi, Z AU - Thomas, L AU - Alexander, JH AU - Amerena, J AU - Hanna, M TI - Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial J2 - Eur Heart J PY - 2012 VL - 33 SP - 2821 EP - 2830 UR - http://dx.doi.org/10.1093/eurheartj/ehs274 ER - TY - JOUR LB - 120. AU - Hori, M AU - Matsumoto, M AU - Tanahashi, N AU - Momomura, S AU - Uchiyama, S AU - Goto, S TI - Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation – the J-ROCKET AF study – J2 - Circ J PY - 2012 VL - 76 SP - 2104 EP - 2111 UR - http://dx.doi.org/10.1253/circj.CJ-12-0454 ER - TY - JOUR LB - 121. AU - Diener, HC AU - Eikelboom, J AU - Connolly, SJ AU - Joyner, CD AU - Hart, RG AU - Lip, GY TI - Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial J2 - Lancet Neurol PY - 2012 VL - 11 SP - 225 EP - 231 UR - http://dx.doi.org/10.1016/S1474-4422(12)70017-0 ER - TY - JOUR LB - 122. AU - Chen, KP AU - Huang, CX AU - Huang, DJ AU - Cao, KJ AU - Ma, CS AU - Wang, FZ AU - Zhang, S TI - Anticoagulation therapy in Chinese patients with non-valvular atrial fibrillation: a prospective, multi-center, randomized, controlled study J2 - Chin Med J PY - 2012 VL - 125 SP - 4355 EP - 4360 ER - TY - JOUR LB - 123. AU - Hankey, GJ AU - Patel, MR AU - Stevens, SR AU - Becker, RC AU - Breithardt, G AU - Carolei, A TI - Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF J2 - Lancet Neurol PY - 2012 VL - 11 SP - 315 EP - 322 UR - http://dx.doi.org/10.1016/S1474-4422(12)70042-X ER - TY - JOUR LB - 124. AU - Easton, JD AU - Lopes, RD AU - Bahit, MC AU - Wojdyla, DM AU - Granger, CB AU - Wallentin, L TI - Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial J2 - Lancet Neurol PY - 2012 VL - 11 SP - 503 EP - 511 UR - http://dx.doi.org/10.1016/S1474-4422(12)70092-3 ER - TY - JOUR LB - 125. AU - Flaker, GC AU - Hohnloser, S AU - Wojdyla, D AU - Hylek, E AU - Garcia, D AU - Sullivan, R TI - Apixaban is efficacious and safe in patients with atrial fibrillation using concomitant amiodarone: an analysis from the ARISTOTLE trial J2 - J Am Coll Cardio PY - 2013 VL - 1 SP - E317 UR - http://dx.doi.org/10.1016/S0735-1097(13)60317-4 ER - TY - JOUR LB - 126. AU - Al-Khatib, SM AU - Thomas, L AU - Wallentin, L AU - Lopes, RD AU - Gersh, B AU - Garcia, D TI - Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial J2 - Eur Heart J PY - 2013 VL - 34 SP - 2464 EP - 2471 UR - http://dx.doi.org/10.1093/eurheartj/eht135 ER - TY - JOUR LB - 127. AU - Bahit, MC AU - Lopes, RD AU - Wojdyla, DM AU - Hohnloser, SH AU - Alexander, JH AU - Lewis, BS TI - Apixaban in patients with atrial fibrillation and prior coronary artery disease: insights from the ARISTOTLE trial J2 - Int J Cardiol PY - 2013 VL - 170 SP - 215 EP - 220 UR - http://dx.doi.org/10.1016/j.ijcard.2013.10.062 ER - TY - JOUR LB - 128. AU - Connolly, SJ AU - Eikelboom, J AU - Dorian, P AU - Hohnloser, SH AU - Gretler, DD AU - Sinha, U AU - Ezekowitz, MD TI - Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa) J2 - Eur Heart J PY - 2013 VL - 34 SP - 1498 EP - 1505 UR - http://dx.doi.org/10.1093/eurheartj/eht039 ER - TY - JOUR LB - 129. AU - Mahaffey, KW AU - Wojdyla, D AU - Hankey, GJ AU - White, HD AU - Nessel, CC AU - Piccini, JP TI - Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial J2 - Ann Intern Med PY - 2013 VL - 158 IS - 12 SP - 861 EP - 868 UR - http://dx.doi.org/10.7326/0003-4819-158-12-201306180-00003 ER - TY - JOUR LB - 130. AU - Garcia, DA AU - Wallentin, L AU - Lopes, RD AU - Thomas, L AU - Alexander, JH AU - Hylek, EM TI - Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial J2 - Am Heart J PY - 2013 VL - 166 SP - 549 EP - 558 UR - http://dx.doi.org/10.1016/j.ahj.2013.05.016 ER - TY - JOUR LB - 131. AU - Giugliano, RP AU - Ruff, CT AU - Braunwald, E AU - Murphy, SA AU - Wiviott, SD AU - Halperin, JL TI - Edoxaban versus warfarin in patients with atrial fibrillation J2 - N Engl J Med PY - 2013 VL - 369 SP - 2093 EP - 2104 UR - http://dx.doi.org/10.1056/NEJMoa1310907 ER - TY - JOUR LB - 132. AU - McMurray, JJ AU - Ezekowitz, JA AU - Lewis, BS AU - Gersh, BJ AU - van Diepen, S AU - Amerena, J TI - Left ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation: insights from the ARISTOTLE trial J2 - Circ Heart Fail PY - 2013 VL - 6 SP - 451 EP - 460 UR - http://dx.doi.org/10.1161/CIRCHEARTFAILURE.112.000143 ER - TY - JOUR LB - 133. AU - Alexander, JH AU - Lopes, RD AU - Thomas, L AU - Alings, M AU - Atar, D AU - Aylward, P TI - Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial J2 - Eur Heart J PY - 2014 VL - 35 SP - 224 EP - 232 UR - http://dx.doi.org/10.1093/eurheartj/eht445 ER - TY - JOUR LB - 134. AU - Hylek, EM AU - Held, C AU - Alexander, JH AU - Lopes, RD AU - De Caterina, R AU - Wojdyla, DM TI - Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes J2 - J Am Coll Cardiol PY - 2014 VL - 63 SP - 2141 EP - 2147 UR - http://dx.doi.org/10.1016/j.jacc.2014.02.549 ER - TY - JOUR LB - 135. AU - Liu, X AU - Huang, H AU - Yu, J AU - Cao, G AU - Feng, L AU - Xu, Q TI - Warfarin compared with aspirin for older Chinese patients with stable coronary heart diseases and atrial fibrillation complications J2 - Int J Clin Pharmacol Ther PY - 2014 VL - 52 SP - 454 EP - 459 UR - http://dx.doi.org/10.5414/CP201996 ER - TY - JOUR LB - 136. AU - Hart, RG AU - Pearce, LA AU - Aguilar, MI TI - Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation J2 - Ann Intern Med PY - 2007 VL - 146 SP - 857 EP - 867 UR - http://dx.doi.org/10.7326/0003-4819-146-12-200706190-00007 ER - TY - JOUR LB - 137. AU - Ezekowitz, MD AU - Bridgers, SL AU - James, KE AU - Carliner, NH AU - Colling, CL AU - Gornick, CC TI - Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators J2 - N Engl J Med PY - 1992 VL - 327 SP - 1406 EP - 1412 UR - http://dx.doi.org/10.1056/NEJM199211123272002 ER - TY - JOUR LB - 138. AU - Cairns, JA TI - Stroke prevention in atrial fibrillation study. Final results J2 - Circulation PY - 1991 VL - 84 SP - 527 EP - 539 UR - http://dx.doi.org/10.1111/j.1524-4733.2006.00085.x ER - TY - JOUR LB - 139. AU - The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators TI - The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation J2 - N Engl J Med PY - 1990 VL - 323 SP - 1505 EP - 1511 UR - http://dx.doi.org/10.1056/NEJM199011293232201 ER - TY - JOUR LB - 140. AU - Connolly, SJ AU - Laupacis, A AU - Gent, M AU - Roberts, RS AU - Cairns, JA AU - Joyner, C TI - Canadian Atrial Fibrillation Anticoagulation (CAFA) Study J2 - J Am Coll Cardiol PY - 1991 VL - 18 SP - 349 EP - 355 UR - http://dx.doi.org/10.1016/0735-1097(91)90585-W ER - TY - JOUR LB - 141. AU - EAFT (European Atrial Fibrillation Trial) Study Group TI - Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke J2 - Lancet PY - 1993 VL - 342 SP - 1255 EP - 1262 ER - TY - JOUR LB - 142. AU - Chimowitz, MI AU - Furlan, AJ TI - Prevention of stroke in atrial fibrillation J2 - N Engl J Med PY - 1990 VL - 323 SP - 481 EP - 484 UR - http://dx.doi.org/10.1056/NEJM199008163230712 ER - TY - JOUR LB - 143. AU - Friberg, L AU - Rosenqvist, M AU - Lip, GY TI - Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study J2 - Eur Heart J PY - 2012 VL - 33 SP - 1500 EP - 1510 UR - http://dx.doi.org/10.1093/eurheartj/ehr488 ER - TY - JOUR LB - 144. AU - Andersen, KK AU - Olsen, TS TI - Reduced poststroke mortality in patients with stroke and atrial fibrillation treated with anticoagulants: results from a Danish quality-control registry of 22,179 patients with ischemic stroke J2 - Stroke PY - 2007 VL - 38 SP - 259 EP - 263 UR - http://dx.doi.org/10.1161/01.STR.0000254622.52483.03 ER - TY - JOUR LB - 145. AU - Hippisley-Cox, J AU - Coupland, C AU - Vinogradova, Y AU - Robson, J AU - Minhas, R AU - Sheikh, A AU - Brindle, P TI - Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2 J2 - BMJ PY - 2008 VL - 336 SP - 1475 EP - 1482 UR - http://dx.doi.org/10.1136/bmj.39609.449676.25 ER - TY - JOUR LB - 146. AU - Office for National Statistics (ONS) TI - National Life Tables, United Kingdom: 2011–13 J2 - Stat Bull PY - 2014 ER - TY - JOUR LB - 147. AU - Heeringa, J AU - van der Kuip, DA AU - Hofman, A AU - Kors, JA AU - van Herpen, G AU - Stricker, BH TI - Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study J2 - Eur Heart J PY - 2006 VL - 27 SP - 949 EP - 953 UR - http://dx.doi.org/10.1093/eurheartj/ehi825 ER - TY - BOOK LB - 148. AU - Office for National Statistics (ONS) TI - 2011 Census, Population and Household Estimates for England and Wales CY - London PB - ONS PY - 2012 ER - TY - JOUR LB - 149. AU - Kamel, H AU - Johnston, SC AU - Easton, JD AU - Kim, AS TI - Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack J2 - Stroke PY - 2012 VL - 43 SP - 881 EP - 883 UR - http://dx.doi.org/10.1161/STROKEAHA.111.641027 ER - TY - JOUR LB - 150. AU - Vanassche, T AU - Lauw, MN AU - Eikelboom, JW AU - Healey, JS AU - Hart, RG AU - Alings, M TI - Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES J2 - Eur Heart J PY - 2015 VL - 36 SP - 281 EP - 27a UR - http://dx.doi.org/10.1093/eurheartj/ehu307 ER - TY - JOUR LB - 151. AU - Hohnloser, SH AU - Pajitnev, D AU - Pogue, J AU - Healey, JS AU - Pfeffer, MA AU - Yusuf, S AU - Connolly, SJ AU - ACTIVE W Investigators TI - Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy J2 - J Am Coll Cardiol PY - 2007 VL - 50 SP - 2156 EP - 2161 UR - http://dx.doi.org/10.1016/j.jacc.2007.07.076 ER - TY - JOUR LB - 152. AU - Leclerc, JR AU - Geerts, WH AU - Desjardins, L AU - Laflamme, GH AU - L’Espérance, B AU - Demers, C TI - Prevention of venous thromboembolism after knee arthroplasty. A randomized, double-blind trial comparing enoxaparin with warfarin J2 - Ann Intern Med PY - 1996 VL - 124 SP - 619 EP - 626 UR - http://dx.doi.org/10.7326/0003-4819-124-7-199604010-00001 ER - TY - JOUR LB - 153. AU - Francis, CW AU - Pellegrini, VD AU - Totterman, S AU - Boyd, AD AU - Marder, VJ AU - Liebert, KM TI - Prevention of deep-vein thrombosis after total hip arthroplasty. Comparison of warfarin and dalteparin J2 - J Bone Joint Surg Am PY - 1997 VL - 79 SP - 1365 EP - 1372 ER - TY - JOUR LB - 154. AU - Colwell, CW AU - Collis, DK AU - Paulson, R AU - McCutchen, JW AU - Bigler, GT AU - Lutz, S AU - Hardwick, ME TI - Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty. Evaluation during hospitalization and three months after discharge J2 - J Bone Joint Surg Am PY - 1999 VL - 81 SP - 932 EP - 940 ER - TY - JOUR LB - 155. AU - Hull, RD AU - Pineo, GF AU - Francis, C AU - Bergqvist, D AU - Fellenius, C AU - Soderberg, K TI - Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: a double-blind, randomized comparison. The North American Fragmin Trial Investigators J2 - Arch Intern Med PY - 2000 VL - 160 SP - 2199 EP - 2207 UR - http://dx.doi.org/10.1001/archinte.160.14.2199 ER - TY - JOUR LB - 156. AU - Fitzgerald, RH, Jr AU - Spiro, TE AU - Trowbridge, AA AU - Gardner, JA, Jr AU - Whitsett, TL AU - O’Connell, MB TI - Prevention of venous thromboembolic disease following primary total knee arthroplasty. A randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin J2 - J Bone Joint Surg Am PY - 2001 VL - 83A SP - 900 EP - 906 ER - TY - JOUR LB - 157. AU - Turpie, AG AU - Fisher, WD AU - Bauer, KA AU - Kwong, LM AU - Irwin, MW AU - Kälebo, P TI - BAY 59–7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study J2 - J Thromb Haemost PY - 2005 VL - 3 SP - 2479 EP - 2486 UR - http://dx.doi.org/10.1111/j.1538-7836.2005.01602.x ER - TY - JOUR LB - 158. AU - Eriksson, BI AU - Borris, LC AU - Dahl, OE AU - Haas, S AU - Huisman, MV AU - Kakkar, AK TI - A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59–7939), for thromboprophylaxis after total hip replacement J2 - Circulation PY - 2006 VL - 114 SP - 2374 EP - 2381 UR - http://dx.doi.org/10.1161/CIRCULATIONAHA.106.642074 ER - TY - JOUR LB - 159. AU - Eriksson, BI AU - Borris, L AU - Dahl, OE AU - Haas, S AU - Huisman, MV AU - Kakkar, AK TI - Oral, direct Factor Xa inhibition with BAY 59–7939 for the prevention of venous thromboembolism after total hip replacement J2 - J Thromb Haemost PY - 2006 VL - 4 SP - 121 EP - 128 UR - http://dx.doi.org/10.1111/j.1538-7836.2005.01657.x ER - TY - JOUR LB - 160. AU - Eriksson, BI AU - Dahl, OE AU - Rosencher, N AU - Kurth, AA AU - van Dijk, CN AU - Frostick, SP TI - Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial J2 - Lancet PY - 2007 VL - 370 SP - 949 EP - 956 UR - http://dx.doi.org/10.1016/S0140-6736(07)61445-7 ER - TY - JOUR LB - 161. AU - Eriksson, BI AU - Dahl, OE AU - Rosencher, N AU - Kurth, AA AU - van Dijk, CN AU - Frostick, SP TI - Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial J2 - J Thromb Haemost PY - 2007 VL - 5 SP - 2178 EP - 2185 UR - http://dx.doi.org/10.1111/j.1538-7836.2007.02748.x ER - TY - JOUR LB - 162. AU - Lassen, MR AU - Davidson, BL AU - Gallus, A AU - Pineo, G AU - Ansell, J AU - Deitchman, D TI - The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement J2 - J Thromb Haemost PY - 2007 VL - 5 SP - 2368 EP - 2375 UR - http://dx.doi.org/10.1111/j.1538-7836.2007.02764.x ER - TY - JOUR LB - 163. AU - Lassen, MR AU - Ageno, W AU - Borris, LC AU - Lieberman, JR AU - Rosencher, N AU - Bandel, TJ TI - Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty J2 - N Engl J Med PY - 2008 VL - 358 SP - 2776 EP - 2786 UR - http://dx.doi.org/10.1056/NEJMoa076016 ER - TY - JOUR LB - 164. AU - Kanan, PS AU - Schwartsmann, CR AU - Boschin, LC AU - Conrad, S AU - Silva, MF TI - Comparative study between rivaroxaban and enoxaparin in deep venous thromboembolism prophylaxis in patients submitted to total hip arthroplasty J2 - Rev Bras Ortop PY - 2008 VL - 43 SP - 319 EP - 328 UR - http://dx.doi.org/10.1590/S0102-36162008000800002 ER - TY - JOUR LB - 165. AU - Eriksson, BI AU - Borris, LC AU - Friedman, RJ AU - Haas, S AU - Huisman, MV AU - Kakkar, AK TI - Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty J2 - N Engl J Med PY - 2008 VL - 358 SP - 2765 EP - 2775 UR - http://dx.doi.org/10.1056/NEJMoa0800374 ER - TY - JOUR LB - 166. AU - Kakkar, AK AU - Brenner, B AU - Dahl, OE AU - Eriksson, BI AU - Mouret, P AU - Muntz, J TI - Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial J2 - Lancet PY - 2008 VL - 372 SP - 31 EP - 39 UR - http://dx.doi.org/10.1016/S0140-6736(08)60880-6 ER - TY - JOUR LB - 167. AU - Ginsberg, JS AU - Davidson, BL AU - Comp, PC AU - Francis, CW AU - Friedman, RJ AU - Huo, MH TI - Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery J2 - J Arthroplasty PY - 2009 VL - 24 SP - 1 EP - 9 UR - http://dx.doi.org/10.1016/j.arth.2008.01.132 ER - TY - JOUR LB - 168. AU - Turpie, AG AU - Bauer, KA AU - Davidson, BL AU - Fisher, WD AU - Gent, M AU - Huo, MH TI - A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT) J2 - Thromb Haemost PY - 2009 VL - 101 SP - 68 EP - 76 ER - TY - JOUR LB - 169. AU - Goel, DP AU - Buckley, R AU - deVries, G AU - Abelseth, G AU - Ni, A AU - Gray, R TI - Prophylaxis of deep-vein thrombosis in fractures below the knee: a prospective randomised controlled trial J2 - J Bone Joint Surg Br PY - 2009 VL - 91 SP - 388 EP - 394 UR - http://dx.doi.org/10.1302/0301-620X.91B3.20820 ER - TY - JOUR LB - 170. AU - Agnelli, G AU - Gussoni, G AU - Bianchini, C AU - Verso, M AU - Mandalà, M AU - Cavanna, L TI - Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study J2 - Lancet Oncol PY - 2009 VL - 10 SP - 943 EP - 949 UR - http://dx.doi.org/10.1016/S1470-2045(09)70232-3 ER - TY - JOUR LB - 171. AU - Lassen, MR AU - Raskob, GE AU - Gallus, A AU - Pineo, G AU - Chen, D AU - Portman, RJ TI - Apixaban or enoxaparin for thromboprophylaxis after knee replacement J2 - N Engl J Med PY - 2009 VL - 361 SP - 594 EP - 604 UR - http://dx.doi.org/10.1056/NEJMoa0810773 ER - TY - JOUR LB - 172. AU - Fuji, T AU - Fujita, S AU - Tachibana, S AU - Kawai, Y TI - Randomized, double-blind, multi-dose efficacy, safety and biomarker study of the oral factor Xa inhibitor DU-176b compared with placebo for prevention of venous thromboembolism in patients after total knee arthroplasty [abstract no. 35] J2 - Blood PY - 2009 VL - 112 IS - 11 SP - 19 ER - TY - JOUR LB - 173. AU - Turpie, AG AU - Lassen, MR AU - Davidson, BL AU - Bauer, KA AU - Gent, M AU - Kwong, LM TI - Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial J2 - Lancet PY - 2009 VL - 373 SP - 1673 EP - 1680 UR - http://dx.doi.org/10.1016/S0140-6736(09)60734-0 ER - TY - JOUR LB - 174. AU - Fuji, T AU - Wang, CJ AU - Fujita, S AU - Tachibana, S AU - Kawai, Y TI - Edoxaban in patients undergoing total hip arthroplasty: A phase IIb dose-finding study J2 - Blood PY - 2009 VL - 114 IS - 22 ER - TY - JOUR LB - 175. AU - Fuji, T AU - Fuijita, S AU - Ujihira, T AU - Sato, T TI - Dabigatran etexilate prevents venous thromboembolism after total knee arthroplasty in Japanese patients with a safety profile comparable to placebo J2 - J Arthroplasty PY - 2010 VL - 25 SP - 1267 EP - 1274 UR - http://dx.doi.org/10.1016/j.arth.2009.08.010 ER - TY - JOUR LB - 176. AU - Lassen, MR AU - Gallus, A AU - Raskob, GE AU - Pineo, G AU - Chen, D AU - Ramirez, LM AU - ADVANCE-3 Investigators TI - Apixaban versus enoxaparin for thromboprophylaxis after hip replacement J2 - N Engl J Med PY - 2010 VL - 363 SP - 2487 EP - 2498 UR - http://dx.doi.org/10.1056/NEJMoa1006885 ER - TY - JOUR LB - 177. AU - Raskob, G AU - Cohen, AT AU - Eriksson, BI AU - Puskas, D AU - Shi, M AU - Bocanegra, T AU - Weitz, JI TI - Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study J2 - Thromb Haemost PY - 2010 VL - 104 SP - 642 EP - 649 UR - http://dx.doi.org/10.1160/TH10-02-0142 ER - TY - JOUR LB - 178. AU - Lassen, MR AU - Raskob, GE AU - Gallus, A AU - Pineo, G AU - Chen, D AU - Hornick, P AU - ADVANCE-2 investigators TI - Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial J2 - Lancet PY - 2010 VL - 375 SP - 807 EP - 815 UR - http://dx.doi.org/10.1016/S0140-6736(09)62125-5 ER - TY - JOUR LB - 179. AU - Fuji, T AU - Fujita, S AU - Tachibana, S AU - Kawai, Y AU - Koretsune, Y AU - Yamashita, T TI - Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: Stars J-V trial [abstract no. 3320] J2 - Blood PY - 2010 VL - 116 IS - 21 ER - TY - JOUR LB - 180. AU - Fuji, T AU - Fujita, S AU - Tachibana, S AU - Kawai, Y TI - A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty J2 - J Thromb Haemost PY - 2010 VL - 8 SP - 2458 EP - 2468 UR - http://dx.doi.org/10.1111/j.1538-7836.2010.04021.x ER - TY - JOUR LB - 181. AU - Fujita, S AU - Fuji, T AU - Tachibana, S AU - Nakamura, M AU - Kawai, Y TI - Safety and efficacy of edoxaban in patients undergoing hip fracture surgery J2 - Pathophysiol Haemost Thromb PY - 2010 VL - 37 SP - A95 ER - TY - JOUR LB - 182. AU - Fuji, T AU - Wang, CJ AU - Fujita, S AU - Tachibana, S AU - Kawai, Y AU - Koretsune, Y TI - Edoxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial J2 - Pathophysiol Haemost Thromb PY - 2010 VL - 37 SP - A20 ER - TY - JOUR LB - 183. AU - Eriksson, B AU - Dahl, OE AU - Kurth, AA AU - Hantel, S AU - Huo, MH AU - Hermansson, K TI - Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty: the RE-NOVATE II randomised trial J2 - Pathophysiol Haemost Thromb PY - 2010 VL - 37 SP - A20 ER - TY - JOUR LB - 184. AU - Cohen, AT AU - Spiro, TE AU - Büller, HR TI - Rivaroxaban compared with enoxaparin for the prevention of venous thromboembolism in acutely ill medical patients: MAGELLAN study methodology J2 - Blood PY - 2010 VL - 116 IS - 21 ER - TY - JOUR LB - 185. AU - Kakkar, AK AU - Cimminiello, C AU - Goldhaber, SZ AU - Parakh, R AU - Wang, C AU - Bergmann, JF AU - LIFENOX Investigators TI - Low-molecular-weight heparin and mortality in acutely ill medical patients J2 - N Engl J Med PY - 2011 VL - 365 SP - 2463 EP - 2472 UR - http://dx.doi.org/10.1056/NEJMoa1111288 ER - TY - JOUR LB - 186. AU - Yokote, R AU - Matsubara, M AU - Hirasawa, N AU - Hagio, S AU - Ishii, K AU - Takata, C TI - Is routine chemical thromboprophylaxis after total hip replacement really necessary in a Japanese population? J2 - J Bone Joint Surg Br PY - 2011 VL - 93 SP - 251 EP - 256 UR - http://dx.doi.org/10.1302/0301-620X.93B2.25795 ER - TY - JOUR LB - 187. AU - Iliopoulos, E AU - Fotiadis, E AU - Kravas, A AU - Vittis, F AU - Nenopoulos, A AU - Ntovas, T TI - Thromboprophylaxis management in total knee arthroplasty J2 - Osteoporos Int PY - 2011 VL - 22 SP - S120 EP - S121 ER - TY - JOUR LB - 188. AU - Goldhaber, SZ AU - Leizorovicz, A AU - Kakkar, AK AU - Haas, SK AU - Merli, G AU - Knabb, RM AU - Weitz, JI AU - ADOPT Trial Investigators TI - Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients J2 - N Engl J Med PY - 2011 VL - 365 SP - 2167 EP - 2177 UR - http://dx.doi.org/10.1056/NEJMoa1110899 ER - TY - JOUR LB - 189. AU - Eriksson, BI AU - Dahl, OE AU - Huo, MH AU - Kurth, AA AU - Hantel, S AU - Hermansson, K TI - Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial J2 - Thromb Haemost PY - 2011 VL - 105 SP - 721 EP - 729 UR - http://dx.doi.org/10.1160/TH10-10-0679 ER - TY - JOUR LB - 190. AU - Levine, MN AU - Gu, C AU - Liebman, HA AU - Escalante, CP AU - Solymoss, S AU - Deitchman, D TI - A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer J2 - J Thromb Haemost PY - 2012 VL - 10 SP - 807 EP - 814 UR - http://dx.doi.org/10.1111/j.1538-7836.2012.04693.x ER - TY - JOUR LB - 191. AU - Cohen, AT AU - Spiro, TE AU - Büller, HR AU - Haskell, L AU - Hu, D AU - Hull, R TI - Rivaroxaban for thromboprophylaxis in acutely ill medical patients J2 - N Engl J Med PY - 2013 VL - 368 SP - 513 EP - 523 UR - http://dx.doi.org/10.1056/NEJMoa1111096 ER - TY - JOUR LB - 192. AU - Zhang, H AU - Wang, D AU - Sun, HY AU - Li, SW AU - Liu, L TI - Efficacy and safety of rivaroxaban in the prevention of deep vein thrombosis after hip arthroplasty J2 - Chin J Tissue Eng Res PY - 2013 VL - 17 SP - 5440 EP - 5445 ER - TY - JOUR LB - 193. AU - Fuji, T AU - Fujita, S AU - Kawai, Y AU - Nakamura, M AU - Kimura, T AU - Kiuchi, Y TI - Safety and efficacy of edoxaban in patients undergoing hip fracture surgery J2 - Thromb Res PY - 2014 VL - 133 SP - 1016 EP - 1022 UR - http://dx.doi.org/10.1016/j.thromres.2014.03.009 ER - TY - JOUR LB - 194. AU - Eriksson, BI AU - Borris, LC AU - Dahl, OE AU - Haas, S AU - Huisman, MV AU - Kakkar, AK TI - Dose-escalation study of rivaroxaban (BAY 59–7939) – an oral, direct Factor Xa inhibitor – for the prevention of venous thromboembolism in patients undergoing total hip replacement J2 - Thromb Res PY - 2007 VL - 120 SP - 685 EP - 693 UR - http://dx.doi.org/10.1016/j.thromres.2006.12.025 ER - TY - JOUR LB - 195. AU - Eriksson, BI AU - Dahl, OE AU - Büller, HR AU - Hettiarachchi, R AU - Rosencher, N AU - Bravo, ML TI - A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial J2 - J Thromb Haemost PY - 2005 VL - 3 SP - 103 EP - 111 UR - http://dx.doi.org/10.1111/j.1538-7836.2004.01100.x ER - TY - JOUR LB - 196. AU - Heit, JA AU - Berkowitz, SD AU - Bona, R AU - Cabanas, V AU - Corson, JD AU - Elliott, CG AU - Lyons, R TI - Efficacy and safety of low molecular weight heparin (ardeparin sodium) compared to warfarin for the prevention of venous thromboembolism after total knee replacement surgery: a double-blind, dose-ranging study. Ardeparin Arthroplasty Study Group J2 - Thromb Haemost PY - 1997 VL - 77 SP - 32 EP - 38 ER - TY - JOUR LB - 197. AU - Haas, SK AU - Freund, M AU - Heigener, D AU - Heilmann, L AU - Kemkes-Matthes, B AU - von Tempelhoff, GF TI - Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer J2 - Clin Appl Thromb Hemost PY - 2012 VL - 18 SP - 159 EP - 165 UR - http://dx.doi.org/10.1177/1076029611433769 ER - TY - JOUR LB - 198. AU - Moise, AI AU - Dragulin, E AU - Casabalian, D AU - Guran, C AU - Mincu, N AU - Stelea, G TI - Dabigatran etexilate Is effective and safe in patients undergoing total hip arthoplasty J2 - Eur J Anaesthesiol PY - 2011 VL - 28 SP - 87 UR - http://dx.doi.org/10.1097/00003643-201106001-00277 ER - TY - JOUR LB - 199. AU - Camporese, G AU - Bernardi, E AU - Noventa, F TI - Efficacy of rivaroxaban for prevention of venous thromboembolism after knee arthroscopy: a randomized double-blind trial (Erika study) J2 - J Thromb Haemost PY - 2011 VL - 9 SP - 156 EP - 157 ER - TY - JOUR LB - 200. AU - van der Veen, L AU - van Raay, JJ AU - Gerritsma-Bleeker, CL AU - Veeger, NJ AU - van Hulst, M TI - Direct treatment comparison of DAbigatran and RIvaroxaban versus NAdroparin in the prevention of venous thromboembolism after total knee arthroplasty surgery: design of a randomised pilot study (DARINA) J2 - BMJ Open PY - 2013 VL - 3 SP - e002218 UR - http://dx.doi.org/10.1136/bmjopen-2012-002218 ER - TY - JOUR LB - 201. AU - Cohen, AT AU - Harrington, R AU - Goldhaber, SZ AU - Hull, R AU - Gibson, CM AU - Hernandez, AF TI - The design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) study J2 - Am Heart J PY - 2014 VL - 167 SP - 335 EP - 341 UR - http://dx.doi.org/10.1016/j.ahj.2013.11.006 ER - TY - JOUR LB - 202. AU - Agnelli, G AU - Gallus, A AU - Goldhaber, SZ AU - Haas, S AU - Huisman, MV AU - Hull, RD TI - Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59–7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59–7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study J2 - Circulation PY - 2007 VL - 116 SP - 180 EP - 187 UR - http://dx.doi.org/10.1161/CIRCULATIONAHA.106.668020 ER - TY - JOUR LB - 203. AU - Büller, HR AU - Lensing, AW AU - Prins, MH AU - Agnelli, G AU - Cohen, A AU - Gallus, AS TI - A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study J2 - Blood PY - 2008 VL - 112 SP - 2242 EP - 2247 UR - http://dx.doi.org/10.1182/blood-2008-05-160143 ER - TY - JOUR LB - 204. AU - Büller, H AU - Deitchman, D AU - Prins, M AU - Segers, A AU - Botticelli Investigators AU - Writing Committee TI - Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study J2 - J Thromb Haemost PY - 2008 VL - 6 SP - 1313 EP - 1318 UR - http://dx.doi.org/10.1111/j.1538-7836.2008.03054.x ER - TY - JOUR LB - 205. AU - Schulman, S AU - Kearon, C AU - Kakkar, AK AU - Mismetti, P AU - Schellong, S AU - Eriksson, H TI - Dabigatran versus warfarin in the treatment of acute venous thromboembolism J2 - N Engl J Med PY - 2009 VL - 361 SP - 2342 EP - 2352 UR - http://dx.doi.org/10.1056/NEJMoa0906598 ER - TY - JOUR LB - 206. AU - Bauersachs, R AU - Berkowitz, SD AU - Brenner, B AU - Büller, HR AU - Decousus, H AU - Gallus, AS TI - Oral rivaroxaban for symptomatic venous thromboembolism J2 - N Engl J Med PY - 2010 VL - 363 SP - 2499 EP - 2510 UR - http://dx.doi.org/10.1056/NEJMoa1007903 ER - TY - JOUR LB - 207. AU - Büller, HR AU - Prins, MH AU - Lensin, AW AU - Decousus, H AU - Jacobson, BF AU - Minar, E TI - Oral rivaroxaban for the treatment of symptomatic pulmonary embolism J2 - N Engl J Med PY - 2012 VL - 366 SP - 1287 EP - 1297 UR - http://dx.doi.org/10.1056/NEJMoa1113572 ER - TY - JOUR LB - 208. AU - Raskob, GE AU - Büller, H AU - Angchaisuksiri, P AU - Oh Boda, Z AU - Lyons, RM TI - Edoxaban for long-term treatment of venous thromboembolism in cancer patients J2 - Blood PY - 2013 VL - 122 IS - 21 ER - TY - JOUR LB - 209. AU - Büller, HR AU - Décousus, H AU - Grosso, MA AU - Mercuri, M AU - Middeldorp, S AU - Prins, MH AU - Hokusai-VTE Investigators TI - Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism J2 - N Engl J Med PY - 2013 VL - 369 SP - 1406 EP - 1415 UR - http://dx.doi.org/10.1056/NEJMoa1306638 ER - TY - JOUR LB - 210. AU - Agnelli, G AU - Büller, HR AU - Cohen, A AU - Curto, M AU - Gallus, AS AU - Johnson, M TI - Oral apixaban for the treatment of acute venous thromboembolism J2 - N Engl J Med PY - 2013 VL - 369 SP - 799 EP - 808 UR - http://dx.doi.org/10.1056/NEJMoa1302507 ER - TY - JOUR LB - 211. AU - Schulman, S AU - Kakkar, AK AU - Goldhaber, SZ AU - Schellong, S AU - Eriksson, H AU - Mismetti, P TI - Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis J2 - Circulation PY - 2014 VL - 129 SP - 764 EP - 772 UR - http://dx.doi.org/10.1161/CIRCULATIONAHA.113.004450 ER - TY - JOUR LB - 212. AU - Young, A AU - Dunn, J AU - Chapman, O AU - Grumett, J AU - Marshall, A AU - Phillips, A TI - SELECT-D: Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism J2 - J Clin Oncol PY - 2014 VL - 32 SP - 5S ER - TY - JOUR LB - 213. AU - Kearon, C AU - Gent, M AU - Hirsh, J AU - Weitz, J AU - Kovacs, MJ AU - Anderson, DR TI - A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism J2 - N Engl J Med PY - 1999 VL - 340 SP - 901 EP - 907 UR - http://dx.doi.org/10.1056/NEJM199903253401201 ER - TY - JOUR LB - 214. AU - Agnelli, G AU - Prandoni, P AU - Santamaria, MG AU - Bagatella, P AU - Iorio, A AU - Bazzan, M TI - Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators J2 - N Engl J Med PY - 2001 VL - 345 SP - 165 EP - 169 UR - http://dx.doi.org/10.1056/NEJM200107193450302 ER - TY - JOUR LB - 215. AU - Agnelli, G AU - Prandoni, P AU - Becattini, C AU - Silingardi, M AU - Taliani, MR AU - Miccio, M TI - Extended oral anticoagulant therapy after a first episode of pulmonary embolism J2 - Ann Intern Med PY - 2003 VL - 139 SP - 19 EP - 25 UR - http://dx.doi.org/10.7326/0003-4819-139-1-200307010-00008 ER - TY - JOUR LB - 216. AU - Ridker, PM AU - Goldhaber, SZ AU - Danielson, E AU - Rosenberg, Y AU - Eby, CS AU - Deitcher, SR TI - Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism J2 - N Engl J Med PY - 2003 VL - 348 SP - 1425 EP - 1434 UR - http://dx.doi.org/10.1056/NEJMoa035029 ER - TY - JOUR LB - 217. AU - Büller, HR TI - Once-daily oral rivaroxaban versus placebo in the long-term prevention of recurrent symptomatic venous thromboembolism. The EINSTEIN-extension study J2 - Blood PY - 2009 VL - 114 SP - 22 ER - TY - JOUR LB - 218. AU - Romualdi, E AU - Donadini, MP AU - Ageno, W TI - Oral rivaroxaban after symptomatic venous thromboembolism: the continued treatment study (EINSTEIN-extension study) J2 - Expert Rev Cardiovasc Ther PY - 2011 VL - 9 SP - 841 EP - 844 UR - http://dx.doi.org/10.1586/erc.11.62 ER - TY - JOUR LB - 219. AU - Becattini, C AU - Agnelli, G AU - Schenone, A AU - Eichinger, S AU - Bucherini, E AU - Silingardi, M TI - Aspirin for preventing the recurrence of venous thromboembolism J2 - N Engl J Med PY - 2012 VL - 366 SP - 1959 EP - 1967 UR - http://dx.doi.org/10.1056/NEJMoa1114238 ER - TY - JOUR LB - 220. AU - Brighton, TA AU - Eikelboom, JW AU - Mann, K AU - Mister, R AU - Gallus, A AU - Ockelford, P TI - Low-dose aspirin for preventing recurrent venous thromboembolism J2 - N Engl J Med PY - 2012 VL - 367 SP - 1979 EP - 1987 UR - http://dx.doi.org/10.1056/NEJMoa1210384 ER - TY - JOUR LB - 221. AU - Agnelli, G AU - Büller, HR AU - Cohen, A AU - Curto, M AU - Gallus, AS AU - Johnson, M TI - Apixaban for extended treatment of venous thromboembolism J2 - N Engl J Med PY - 2013 VL - 368 SP - 699 EP - 708 UR - http://dx.doi.org/10.1056/NEJMoa1207541 ER - TY - JOUR LB - 222. AU - Schulman, S AU - Kearon, C AU - Kakkar, AK AU - Schellong, S AU - Eriksson, H AU - Baanstra, D TI - Extended use of dabigatran, warfarin, or placebo in venous thromboembolism J2 - N Engl J Med PY - 2013 VL - 368 SP - 709 EP - 718 UR - http://dx.doi.org/10.1056/NEJMoa1113697 ER - TY - JOUR LB - 223. AU - Tullett, J AU - Murray, E AU - Nichols, L AU - Holder, R AU - Lester, W AU - Rose, P TI - Trial Protocol: a randomised controlled trial of extended anticoagulation treatment versus routine anticoagulation treatment for the prevention of recurrent VTE and post thrombotic syndrome in patients being treated for a first episode of unprovoked VTE (The ExACT Study) J2 - BMC Cardiovasc Disord PY - 2013 VL - 13 SP - 16 UR - http://dx.doi.org/10.1186/1471-2261-13-16 ER - TY - JOUR LB - 224. AU - Mazilu, L AU - Parepa, IR AU - Suceveanu, AI AU - Suceveanu, A AU - Baz, R AU - Catrinoiu, D TI - Venous thromboembolism: secondary prevention with dabigatran vs. acenocumarolin patients with paraneoplastic deep vein thrombosis. Results from a small prospective study in Romania J2 - Cardiovasc Res PY - 2014 VL - 103 SP - S39 UR - http://dx.doi.org/10.1093/cvr/cvu082.154 ER - TY - JOUR LB - 225. AU - White, HD TI - Editorial: do we need another bleeding definition? What does the Bleeding Academic Research Consortium definition have to offer? J2 - Curr Opin Cardiol PY - 2011 VL - 26 SP - 275 EP - 278 UR - http://dx.doi.org/10.1097/HCO.0b013e32834706a9 ER - TY - JOUR LB - 226. AU - Hart, RG AU - Diener, HC AU - Yang, S AU - Connolly, SJ AU - Wallentin, L AU - Reilly, PA TI - Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial J2 - Stroke PY - 2012 VL - 43 SP - 1511 EP - 1517 UR - http://dx.doi.org/10.1161/STROKEAHA.112.650614 ER - TY - JOUR LB - 227. AU - Prandoni, P AU - Villalta, S AU - Bagatella, P AU - Rossi, L AU - Marchiori, A AU - Piccioli, A TI - The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients J2 - Haematologica PY - 1997 VL - 82 SP - 423 EP - 428 ER - TY - JOUR LB - 228. AU - Prandoni, P AU - Noventa, F AU - Ghirarduzzi, A AU - Pengo, V AU - Bernardi, E AU - Pesavento, R TI - The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients J2 - Haematologica PY - 2007 VL - 92 SP - 199 EP - 205 UR - http://dx.doi.org/10.3324/haematol.10516 ER - TY - JOUR LB - 229. AU - Pengo, V AU - Lensing, AW AU - Prins, MH AU - Marchiori, A AU - Davidson, BL AU - Tiozzo, F TI - Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism J2 - N Engl J Med PY - 2004 VL - 350 SP - 2257 EP - 2264 UR - http://dx.doi.org/10.1056/NEJMoa032274 ER - TY - JOUR LB - 230. AU - Akaike, H TI - A new look at the statistical model identification J2 - IEEE Trans Automat Contr PY - 1974 VL - 19 SP - 716 EP - 723 UR - http://dx.doi.org/10.1109/TAC.1974.1100705 ER - TY - JOUR LB - 231. AU - Fenwick, E AU - Byford, S TI - A guide to cost-effectiveness acceptability curves J2 - Br J Psychiatry PY - 2005 VL - 187 SP - 106 EP - 108 UR - http://dx.doi.org/10.1192/bjp.187.2.106 ER - TY - JOUR LB - 232. AU - Hamidi, V AU - Ringerike, T AU - Hagen, G AU - Reikvam, A AU - Klemp, M TI - New anticoagulants as thromboprophylaxis after total hip or knee replacement J2 - Int J Technol Assess Health Care PY - 2013 VL - 29 SP - 234 EP - 243 UR - http://dx.doi.org/10.1017/S0266462313000251 ER - TY - JOUR LB - 233. AU - Lefebvre, P AU - Coleman, CI AU - Bookhart, BK AU - Wang, ST AU - Mody, SH AU - Tran, KN TI - Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism J2 - J Med Econ PY - 2014 VL - 17 SP - 52 EP - 64 UR - http://dx.doi.org/10.3111/13696998.2013.858634 ER - TY - JOUR LB - 234. AU - Liew, A AU - Eikelboom, JW AU - O’Donnell, M AU - Hart, RG TI - Assessment of anticoagulation intensity and management of bleeding with old and new oral anticoagulants J2 - Can J Cardiol PY - 2013 VL - 29 IS - Suppl. 7 SP - 34 EP - 44 UR - http://dx.doi.org/10.1016/j.cjca.2013.04.013 ER - TY - JOUR LB - 235. AU - Yang, E TI - A clinician’s perspective: novel oral anticoagulants to reduce the risk of stroke in nonvalvular atrial fibrillation – full speed ahead or proceed with caution? J2 - Vasc Health Risk Manag PY - 2014 VL - 10 SP - 507 EP - 522 UR - http://dx.doi.org/10.2147/VHRM.S68117 ER - TY - JOUR LB - 236. AU - Fenger-Eriksen, C AU - Münster, AM AU - Grove, EL TI - New oral anticoagulants: clinical indications, monitoring and treatment of acute bleeding complications J2 - Acta Anaesthesiol Scand PY - 2014 VL - 58 SP - 651 EP - 659 UR - http://dx.doi.org/10.1111/aas.12319 ER - TY - ELEC LB - 237. AU - UKMi New Drugs Online Database TI - New Drugs Online Report for Ciraparantag UR - www.ukmi.nhs.uk/applications/ndo/record_view_open.asp?newDrugID=6443 M1 - 18 May 2015 ER - TY - JOUR LB - 238. AU - Ansell, JE AU - Bakhru, SH AU - Laulicht, BE AU - Steiner, SS AU - Grosso, M AU - Brown, K TI - Use of PER977 to reverse the anticoagulant effect of edoxaban J2 - N Engl J Med PY - 2014 VL - 371 SP - 2141 EP - 2142 UR - http://dx.doi.org/10.1056/NEJMc1411800 ER - TY - JOUR LB - 239. AU - Lu, G AU - DeGuzman, FR AU - Hollenbach, SJ AU - Karbarz, MJ AU - Abe, K AU - Lee, G TI - A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa J2 - Nat Med PY - 2013 VL - 19 SP - 446 EP - 451 UR - http://dx.doi.org/10.1038/nm.3102 ER - TY - ELEC LB - 240. AU - UKMi New Drugs Online Database TI - New Drugs Online Report for Andexanet Alfa UR - www.ukmi.nhs.uk/applications/ndo/record_view_open.asp?newDrugID=6169 M1 - 18 May 2015 ER - TY - JOUR LB - 241. AU - Schiele, F AU - van Ryn, J AU - Canada, K AU - Newsome, C AU - Sepulveda, E AU - Park, J TI - A specific antidote for dabigatran: functional and structural characterization J2 - Blood PY - 2013 VL - 121 SP - 3554 EP - 3562 UR - http://dx.doi.org/10.1182/blood-2012-11-468207 ER - TY - ELEC LB - 242. AU - UKMi New Drugs Online Database TI - New Drugs Online Report for Idarucizumab UR - www.ukmi.nhs.uk/applications/ndo/record_view_open.asp?newDrugID=6275 M1 - 18 May 2015 ER - TY - ELEC LB - 243. AU - Framingham Heart Study CY - Boston, MA UR - www.framinghamstudy.org M1 - 22 August 2016 ER - TY - JOUR LB - 244. AU - Sorensen, SV AU - Dewilde, S AU - Singer, DE AU - Goldhaber, SZ AU - Monz, BU AU - Plumb, JM TI - Cost-effectiveness of warfarin: trial versus “real-world” stroke prevention in atrial fibrillation J2 - Am Heart J PY - 2009 VL - 157 SP - 1064 EP - 1073 UR - http://dx.doi.org/10.1016/j.ahj.2009.03.022 ER - TY - JOUR LB - 245. AU - Roskell, NS AU - Lip, GY AU - Noack, H AU - Clemens, A AU - Plumb, JM TI - Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate J2 - Thromb Haemost PY - 2010 VL - 104 SP - 1106 EP - 1115 UR - http://dx.doi.org/10.1160/TH10-10-0642 ER -